622 related articles for article (PubMed ID: 15657340)
1. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
2. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
Vaissière T; Sawan C; Herceg Z
Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
[TBL] [Abstract][Full Text] [Related]
7. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.
Wang LG; Beklemisheva A; Liu XM; Ferrari AC; Feng J; Chiao JW
Mol Carcinog; 2007 Jan; 46(1):24-31. PubMed ID: 16921492
[TBL] [Abstract][Full Text] [Related]
8. Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.
Baylin SB
Novartis Found Symp; 2004; 259():226-33; discussion 234-7, 285-8. PubMed ID: 15171257
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
Grønbaek K; Treppendahl M; Asmar F; Guldberg P
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
11. Methylated genes as potential biomarkers in prostate cancer.
Phé V; Cussenot O; Rouprêt M
BJU Int; 2010 May; 105(10):1364-70. PubMed ID: 20067451
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics in bladder cancer.
Enokida H; Nakagawa M
Int J Clin Oncol; 2008 Aug; 13(4):298-307. PubMed ID: 18704629
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic mechanisms in the biology of prostate cancer.
Schulz WA; Hoffmann MJ
Semin Cancer Biol; 2009 Jun; 19(3):172-80. PubMed ID: 19429481
[TBL] [Abstract][Full Text] [Related]
15. [Epigenome and cancer: new possibilities of cancer prevention and therapy?].
Paluszczak J; Baer-Dubowska W
Postepy Biochem; 2005; 51(3):244-50. PubMed ID: 16381168
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic mechanisms in cancer.
Banerjee HN; Verma M
Biomark Med; 2009 Aug; 3(4):397-410. PubMed ID: 20477485
[TBL] [Abstract][Full Text] [Related]
18. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
19. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic changes in cancer.
Grønbaek K; Hother C; Jones PA
APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
